| 我国生物制药上市公司投资风险评价——基于主成分-聚类分析法 |
| |
| 引用本文： | 王瑞红,王筱萍,薛耀文.我国生物制药上市公司投资风险评价——基于主成分-聚类分析法[J].技术经济,2011,30(10):76-80. |
| |
| 作者姓名： | 王瑞红 王筱萍 薛耀文 |
| |
| 作者单位： | 1. 太原科技大学经济与管理学院,太原,030024
2. 山西师范大学经济管理学院,山西临汾,041004 |
| |
| 基金项目： | 教育部人文社会科学研究规划基金项目，山西省软科学项目“基于嵌套copula函数的金融产品风险管理问题研究” |
| |
| 摘 要： | 以我国15家生物制药行业上市公司为研究样本,利用聚类分析法,对15家生物制药行业上市公司进行聚类识别,将样本公司分为3类;对投资风险评价指标进行主成分分析,据此计算了15家样本公司的投资风险,并根据比较结果进行了排序。结果表明,我国多数生物制药上市公司的投资风险均衡。
|
| 关 键 词： | 风险投资 投资风险 风险评价 生物制药产业 高新技术产业 |
Evaluation on Risk of Investing in Listed Companies in Biopharmaceutical Industry： Based on Method of Principal Component and Clustering Analysis |
| |
| Wang Ruihong,Wang Xiaoping,Xue Yaowen.Evaluation on Risk of Investing in Listed Companies in Biopharmaceutical Industry： Based on Method of Principal Component and Clustering Analysis[J].Technology Economics,2011,30(10):76-80. |
| |
| Authors: | Wang Ruihong Wang Xiaoping Xue Yaowen |
| |
| Institution: | 1.School of Economics and Management,Taiyuan University of Science and Technology,Taiyuan 030024,China;2.School of Economics and Management,Shanxi Normal University,Linfen Shanxi 041004,China) |
| |
| Abstract: | This paper takes 15 listed companies in biopharmaceutical industry as the research example,and divides these companies into three clusters by the method of cluster analysis. And it makes a principal component analysis on the evaluation index of investment risk,and calculates the investment risks of 15 sample companies,and sorts these companies according to the evaluation result. The result shows that most of listed companies in biopharmaceutical industry have balanced investment risk. |
| |
| Keywords: | venture capital investment risk risk evaluation biopharmaceutical industry high-tech industry |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
